AR107983A1 - Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1 - Google Patents

Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1

Info

Publication number
AR107983A1
AR107983A1 ARP170100748A ARP170100748A AR107983A1 AR 107983 A1 AR107983 A1 AR 107983A1 AR P170100748 A ARP170100748 A AR P170100748A AR P170100748 A ARP170100748 A AR P170100748A AR 107983 A1 AR107983 A1 AR 107983A1
Authority
AR
Argentina
Prior art keywords
antibody
integrin
vedolizumab
ctla4
immune system
Prior art date
Application number
ARP170100748A
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR107983A1 publication Critical patent/AR107983A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Métodos para reducir eventos adversos gastrointestinales relacionados con el sistema inmunitario, tales como colitis y diarrea, en sujetos que se someten a un tratamiento inmunológico, tal como un tratamiento de; oncología inmunológica, tal como un tratamiento de combinación de anticuerpo anti-CTLA4 y un anticuerpo anti-PD-1 para melanomas. En determinados aspectos, los métodos comprenden administrar una cantidad terapéuticamente eficaz de un polipéptido que inhibe la unión de MAdCAM-integrina, tal como un anticuerpo anti-a4b7 integrina, tal como vedolizumab o un anticuerpo relacionado. | Reivindicación 1: Un método para tratar un evento adverso gastrointestinal relacionado con el sistema inmunitario (gi-irAE) en un sujeto mamífero que se somete a un tratamiento con un antagonista de PD-1, un anticuerpo anti-CTLA4, o un antagonista de PD-1 y un anticuerpo anti-CTLA4, que comprende administrar una cantidad terapéuticamente eficaz de un polipéptido que inhibe la unión de MAdCAM-a4b7 integrina al sujeto. Reivindicación 2: El método de la reivindicación 1, en donde el polipéptido que inhibe la unión de MAdCAM-a4b7 integrina es un anticuerpo anti-a4b7 integrina, como un anticuerpo anti-a4b7 integrina que compite con vedolizumab para unir a4b7 integrina, más particularmente, en donde el anticuerpo tiene la especificidad epitópica de vedolizumab, más particularmente en donde el anticuerpo comprende las regiones determinantes de complementariedad (CDR) de vedolizumab, y aun más particularmente en donde el anticuerpo es vedolizumab.
ARP170100748A 2016-03-24 2017-03-27 Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1 AR107983A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662312826P 2016-03-24 2016-03-24

Publications (1)

Publication Number Publication Date
AR107983A1 true AR107983A1 (es) 2018-07-04

Family

ID=58489429

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100748A AR107983A1 (es) 2016-03-24 2017-03-27 Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1

Country Status (3)

Country Link
AR (1) AR107983A1 (es)
TW (1) TW201735949A (es)
WO (1) WO2017165742A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7202893B2 (ja) 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
CN111944850B (zh) * 2020-08-28 2023-03-31 澳门大学 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用
WO2022178557A2 (en) * 2021-02-22 2022-08-25 Pandion Operations, Inc. Pancreas targeted therapeutics and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US748802A (en) 1904-01-05 Territory
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
DK0808367T3 (da) 1995-02-10 2007-11-05 Millennium Pharm Inc Vaskulære slimhindeaddressiner samt anvendelse deraf
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7322582B2 (en) 2003-07-17 2008-01-29 Mind Wurx, Llc Enhanced shopping cart with lowered center of gravity and frame therefor
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP1791866A2 (en) 2004-08-11 2007-06-06 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
SI3530673T1 (sl) 2004-09-03 2022-08-31 Genentech, Inc. Humanizirani antagonisti proti beta7 in njihove uporabe
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
MX2008013057A (es) 2006-04-14 2009-04-07 Trubion Pharmaceuticals Inc Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
US20100330093A1 (en) 2007-12-12 2010-12-30 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
EP2408816B1 (en) 2009-03-20 2019-09-04 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
WO2012027536A1 (en) 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
WO2013019620A2 (en) 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US20140323533A1 (en) 2013-04-29 2014-10-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
WO2015125159A1 (en) 2014-02-21 2015-08-27 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112016026197A2 (pt) 2014-05-13 2018-02-20 Medimmune Limited anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de câncer de pulmão de não pequenas células
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP3012270A1 (en) * 2014-10-23 2016-04-27 Institut Gustave Roussy Products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker

Also Published As

Publication number Publication date
WO2017165742A1 (en) 2017-09-28
TW201735949A (zh) 2017-10-16

Similar Documents

Publication Publication Date Title
AR107983A1 (es) Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1
CL2019000760A1 (es) Tratamiento de migraña refractaria
NI201700015A (es) Tratamientos conjuntos con anticuerpos anti cd40
PH12018502046A1 (en) Methods for inhibiting angiogenesis in a subject in need thereof
PH12021550023A1 (en) Humanized anti-tau antibodies
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
UY37336A (es) Anticuerpos anti-virus del zika y métodos de uso
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
BR112018072723A2 (pt) composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
BR112017020002A2 (pt) Combinação de inibidor de hdac e anticorpo anti- pd-1 para o tratamento de câncer
AU2019243283C1 (en) Methods of treating ulcerative colitis
BR112017002433A2 (pt) anticorpos anticeramida
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA202191666A1 (ru) Антитела к il-27 и их применение
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
NZ729878A (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников

Legal Events

Date Code Title Description
FB Suspension of granting procedure